GLOBAL AUTOIMMUNE POLYGLANDULAR SYNDROME TYPE 1 MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Global Autoimmune Polyglandular Syndrome Type 1 Market, By Diagnosis (Serum Autoimmune Screen, End-organ Function Tests, Blood Tests), By Treatment (Medication, Antifungal Agents, Fluconazole, Itraconazole, Calcitriol, Corticosteroids, Others), By Dosage Form (Tablet, Capsule, Others), By Route of Administration (Oral, Others), By Age of Onset (Childhood, Adult, Adolescent), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

Published In : Jan 2024
Code : CMI6538
Pages :172
Formats :
Excel and PDF
Industry : Pharmaceutical

Global Autoimmune Polyglandular Syndrome Type 1 Market Size and Trends

The global autoimmune polyglandular syndrome type 1 market size is expected to reach US$ 317.9 Mn by 2030, from US$ 257 Mn in 2023, exhibiting a CAGR of 3.1% during the forecast period.

Global Autoimmune Polyglandular Syndrome Type 1 Market- Trends

Precision and personalized medicine: The growing field of precision and personalized medicine is having a significant impact on the autoimmune polyglandular syndrome type 1 (APS1) market. APS1 is a rare genetic disorder that causes multiple endocrine gland failures. With advances in genetic testing and profiling, researchers are gaining a much deeper understanding of the molecular mechanisms behind APS1. By identifying specific gene mutations and variants associated with individual patients, doctors can develop highly tailored treatment plans based on a person's unique genetic profile and predicted disease progression. This represents a shift away from traditional one-size-fits-all therapies towards precise interventions designed for individual patients. Several biotech companies are now developing gene-targeted drugs that aim to suppress faulty immune responses at the genetic level in APS1. For example, Boston, U.S.-based Bit Bio, an award-winning spinout from the University of Cambridge recently launched a phase 2 trial of an IL-21 monoclonal antibody for APS1 caused by AIRE gene mutations (source: clinicaltrials.gov). By homing in on the specific dysfunctional immune pathways driving a person's APS1, these precision medicines have the potential for much higher response rates compared to traditional broad immunosuppressants.
Stem cell therapy research: Recent advancements in stem cell therapy research have shown promising results for treating a variety of autoimmune conditions. This includes early phase clinical trials investigating the use of stem cells to treat autoimmune polyglandular syndrome type 1 (APS-1), a rare genetic disorder characterized by simultaneous dysfunction of multiple endocrine glands. In APS-1, the immune system mistakenly attacks and destroys insulin-producing cells in the pancreas and other hormone-producing glands. Conventional treatment focuses on replacing lost hormones and managing symptoms, but it does not cure the underlying immune dysfunction.